Group 1 - The core point of the article is that Meikang Bio (SZ 300439) announced that its subsidiary, Jiangxi Meikang Shengde Biotechnology Co., Ltd., has obtained a medical device registration certificate for the "Heparin Binding Protein Test Kit" from the Jiangxi Provincial Drug Administration [1] - For the year 2024, Meikang Bio's revenue composition is expected to be 100% from medical devices [1] - As of the time of reporting, Meikang Bio has a market capitalization of 4.1 billion yuan [1] Group 2 - The article also mentions that prior to the arrest of Xu Xiren, the chairman of Peking University Medicine, the police had investigated the group's factory premises [1] - Internal sources indicate that the group's assets have been disposed of by Xu, with a significant amount of funds unaccounted for [1]